Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$73.94M

FY 2025 · Annual

Investing Cash Flow

-$5.45M

FY 2025 · Annual

Financing Cash Flow

-$8.05M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Depreciation & Amortization1.25M1.29M843K1.15M2.96M
Deferred Income Tax2.4M(21.4M)(19M)287K(9.19M)
Stock-Based Compensation7.72M11.19M22.52M6.58M10.52M
Change in Working Capital(48.19M)(60.38M)4.97M(5.79M)(8.06M)
Accounts Receivables(2.69M)3.32M907K7.98M(243K)
Inventory211K920K000
Accounts Payables(219K)92K2.83M(2.93M)1.07M
Other Working Capital(45.5M)(64.71M)1.23M(10.84M)(8.89M)
Other Non-Cash Items2.13M2.29M159.21M51.52M60.14M
Operating Cash Flow(60.38M)(31.63M)(51.16M)(23.67M)(73.94M)
Capital Expenditures(1.09M)(1.2M)(206K)(9.09M)(5.45M)
Acquisitions (Net)006.56M351K0
Purchases of Investments(32.46M)(33.5M)000
Sales of Investments16.4M19.7M28.25M00
Other Investing Activities00000
Investing Cash Flow(17.14M)(15M)34.61M(8.74M)(5.45M)
Debt Repayment00(27.46M)00
Common Stock Issued51.96M38.98M0124.44M(301K)
Common Stock Repurchased00(6.17M)00
Dividends Paid00000
Other Financing Activities939K235K231K3.99M(7.75M)
Financing Cash Flow52.9M39.22M(13.15M)168.43M(8.06M)
Effect of Forex Changes(3K)20K(53K)(21K)45K
Net Change in Cash(24.63M)(7.4M)(29.75M)135.99M(87.41M)
Free Cash Flow(61.47M)(32.83M)(51.37M)(32.77M)(79.4M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$130.3M
+ D&A$3.0M
+ Stock-Based Comp$10.5M
- Deferred Tax-$9.2M
- Working Capital-$8.1M
+ Other Non-Cash$60.1M
= Operating Cash Flow-$73.9M
- Capex-$5.5M
= Free Cash Flow-$79.4M

Analysis

FY2025 free cash flow is -$79.4M. FCF conversion is 60.9% of net income. Operating cash flow was -$73.9M, with capex of -$5.5M. The largest bridge item is Other Non-Cash at $60.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 6, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportSep 29, 2026
SC 13GSC 13G filingAug 13, 2026

Does RNAC generate free cash flow?

Cartesian Therapeutics, Inc. (RNAC) generated -$79.39M of free cash flow in fiscal 2025.

How much operating cash flow does RNAC produce?

Operating cash flow was -$73.94M, before capital expenditures of $5.45M.